Sign In
Buy BIVI
$1.65
-0.0500 (-2.94%)
At Close: Jun 03, 2026
New Strong Buy Stocks for October 19th
08:16am, Thursday, 19'th Oct 2023
INTA, NU, ENLV, VCEL and BIVI have been added to the Zacks Rank #1 (Strong Buy) List on October 19, 2023.
BioVie complements its Alzheimer's clinical research program with social impact initiatives
03:29pm, Tuesday, 26'th Sep 2023
What sets BioVie Inc (NASDAQ:BIVI) apart from many of its biotechnology peers is the fact it has appointed a Chief Social Impact Officer whose role is to drive the company's people-focused social impa
BioVie to announce topline data from Phase 3 Alzheimer's Disease trial by year-end
09:11am, Tuesday, 26'th Sep 2023
BioVie Inc (NASDAQ:BIVI) said the last patient has completed their final visit at week 30 in their Phase 3 study of investigational therapy NE3107 in patients with mild to moderate Alzheimer's Diseas
BioVie to Participate in the Cantor Fitzgerald Global Healthcare Conference
08:00am, Tuesday, 19'th Sep 2023
CARSON CITY, Nev., Sept. 19, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of
BioVie presents Alzheimer's study data on patient's baseline characteristics
08:42am, Monday, 11'th Sep 2023
BioVie Inc (NASDAQ:BIVI) has unveiled early data from its Phase 3 study of its investigational drug NE3107 in patients with mild to moderate Alzheimer's Disease, highlighting the preliminary baseline
Top 5 Health Care Stocks That May Explode In Q3 - BioVie (NASDAQ:BIVI), Galera Therapeutics (NASDAQ:GRTX)
07:36am, Wednesday, 06'th Sep 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Down -26.93% in 4 Weeks, Here's Why BioVie Inc. (BIVI) Looks Ripe for a Turnaround
11:17am, Wednesday, 30'th Aug 2023
The heavy selling pressure might have exhausted for BioVie Inc. (BIVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analyst
Down -29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in BioVie Inc. (BIVI)
11:17am, Monday, 28'th Aug 2023
BioVie Inc. (BIVI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revisi
BioVie showcases promising data for NE3107 at international Parkinson's Disease event
09:06am, Monday, 28'th Aug 2023
BioVie Inc (NASDAQ:BIVI) said new preclinical data characterizing its lead drug candidate NE3107's mechanism in action is being presented at the 2023 International Congress of Parkinson's Disease and
Down -23.45% in 4 Weeks, Here's Why You Should You Buy the Dip in BioVie Inc. (BIVI)
11:17am, Thursday, 24'th Aug 2023
The heavy selling pressure might have exhausted for BioVie Inc. (BIVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analyst
BioVie updates on its progress and recent findings
08:17am, Tuesday, 18'th Jul 2023
BioVie Inc (NASDAQ:BIVI) has issued a letter to shareholders providing an update on its progress and recent findings. The letter highlights the company's excitement and optimism regarding the Phase 3
BioVie's clinical dementia drug NE3107 shown to reduce DNA methylation
09:09am, Monday, 17'th Jul 2023
BioVie Inc (NASDAQ:BIVI) presented a poster over the weekend showcasing the epigenetic basis for how its drug candidate NE3107 may have regulated specific genes in a way that delivers cognitive improv
Leqembi approval offers renewed hope for novel Alzheimer's disease treatments
04:43pm, Monday, 10'th Jul 2023
US officials have granted full approval to Leqembi, the first medication to demonstrate modest effectiveness in slowing cognitive decline associated with Alzheimer's disease. Developed by Japanese dru
BioVie to present promising new data for drug candidate NE3107 at Alzheimer's conference
09:18am, Monday, 10'th Jul 2023
BioVie Inc (NASDAQ:BIVI) announced that a poster detailing how its drug candidate NE3107 regulated specific genes in a way significantly correlated with observed cognitive and biomarker improvements w
CARSON CITY, Nev., July 10, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of
